Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Moligand™, ≥99% Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C,Argon charged Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 15 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Lonidamine is an indazole compound that has been reported to inhibit angiogenic-related endothelial cell functions. This compound has been found to trigger apoptosis in endothelial cells and cause a decrease in proliferation, migration, invasion, and morphogenesis. The apoptotic effects of Lonidamine have been demonstrated to be due to Bax, Bid, caspase-3, and caspase-9 activation, as well as cytochrome c release. Futher studies show that Lonidamine prevents cellular energy metabolism via HXK (hexokinase) inhibition. This compound also blocks CFTR Cl- channels in vitro.
It elicits cell apoptosis and blocks CFTR Cl- channel.
| Pubchem Sid | 504753590 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504753590 |
| Sonrisas canónicas | C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Cl)Cl)C(=O)O |
| IUPAC Name | 1-[(2,4-dichlorophenyl)methyl]indazole-3-carboxylic acid |
| InChIKey | WDRYRZXSPDWGEB-UHFFFAOYSA-N |
| INCHI | 1S/C15H10Cl2N2O2/c16-10-6-5-9(12(17)7-10)8-19-13-4-2-1-3-11(13)14(18-19)15(20)21/h1-7H,8H2,(H,20,21) |
| Isómeros SMILES | C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Cl)Cl)C(=O)O |
| WGK Alemania | 3 |
| CAS alternativo | 50264-69-2 |
| Número NSC | 741419 |
| Términos de entrada MeSH | 1-(2,4-dichlorobenzyl)indazole-3-carboxylic acid;AF 1890;diclondazolic acid;lonidamine |
| Peso molecular | 321.16 |
| Reaxy-Rn | 894483 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=894483&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| Clase | Benzopyrazoles |
| Subclass | Indazoles |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Indazoles |
| Alternative Parents | Pyrazole carboxylic acids and derivatives Dichlorobenzenes Aryl chlorides Heteroaromatic compounds Monocarboxylic acids and derivatives Carboxylic acids Azacyclic compounds Organopnictogen compounds Organooxygen compounds Organonitrogen compounds Organochlorides Organic oxides Hydrocarbon derivatives |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Benzopyrazole - Indazole - Pyrazole-3-carboxylic acid or derivatives - Pyrazole-5-carboxylic acid or derivatives - 1,3-dichlorobenzene - Chlorobenzene - Halobenzene - Aryl chloride - Aryl halide - Monocyclic benzene moiety - Benzenoid - Azole - Heteroaromatic compound - Pyrazole - Carboxylic acid derivative - Carboxylic acid - Azacycle - Monocarboxylic acid or derivatives - Organooxygen compound - Organic oxygen compound - Organic nitrogen compound - Hydrocarbon derivative - Organic oxide - Organonitrogen compound - Organochloride - Organopnictogen compound - Organohalogen compound - Aromatic heteropolycyclic compound |
| Descripción | This compound belongs to the class of organic compounds known as indazoles. These are compounds containing an indazole, which is structurally characterized by a pyrazole fused to a benzene. |
| External Descriptors | monocarboxylic acid - dichlorobenzene - indazoles |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Fecha | Articulo |
|---|---|---|---|
| Certificate of Analysis | Mar 13, 2026 | L129342 | |
| Certificate of Analysis | Oct 14, 2025 | L129342 | |
| Certificate of Analysis | Oct 14, 2025 | L129342 | |
| Certificate of Analysis | Aug 11, 2025 | L129342 | |
| Certificate of Analysis | Jul 09, 2025 | L129342 | |
| Certificate of Analysis | Apr 30, 2025 | L129342 | |
| Certificate of Analysis | Apr 30, 2025 | L129342 | |
| Certificate of Analysis | Apr 30, 2025 | L129342 | |
| Certificate of Analysis | Apr 30, 2025 | L129342 | |
| Certificate of Analysis | Apr 30, 2025 | L129342 | |
| Certificate of Analysis | Apr 30, 2025 | L129342 | |
| Certificate of Analysis | Apr 30, 2025 | L129342 | |
| Certificate of Analysis | Jan 09, 2025 | L129342 | |
| Certificate of Analysis | Jan 09, 2025 | L129342 | |
| Certificate of Analysis | Jun 12, 2022 | L129342 | |
| Certificate of Analysis | Jun 12, 2022 | L129342 | |
| Certificate of Analysis | Jun 12, 2022 | L129342 | |
| Certificate of Analysis | Jun 12, 2022 | L129342 | |
| Certificate of Analysis | Jun 12, 2022 | L129342 |
| Solubilidad | Soluble in ethanol (5 mM), DMSO (100 mM), CHCl3/MeOH 1/1 (9.80-10.20 mg/ml), water (<1 mg/ml at 25° C), DMSO (64 mg/ml at 25° C), and ethanol (<1 mg/ml at 25° C). |
|---|---|
| Sensibilidad | Air Sensitive |
| Punto de fusión (°C) | 210 °C |
| Peso molecular | 321.200 g/mol |
| XLogP3 | 4.300 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 320.012 Da |
| Monoisotopic Mass | 320.012 Da |
| Topological Polar Surface Area | 55.100 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 396.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
| 1. Chen Huan, Li Ting, Liu Zhiyong, Tang Shuwan, Tong Jintao, Tao Yingfang, Zhao Zinan, Li Nan, Mao Chun, Shen Jian, Wan Mimi. (2023) A nitric-oxide driven chemotactic nanomotor for enhanced immunotherapy of glioblastoma. Nature Communications, 14 (1): (1-21). [PMID:36804924] [10.1038/s41467-022-35709-0] |
| 2. Lu Yang, Junnan Li, Zhaoyuan Guan, Jingwen Zhang, Xin Wang, Rupei Tang. (2022) Carrier-free prodrug nanoparticles based on lonidamine and cisplatin for synergistic treatment of breast cancer. JOURNAL OF BIOMATERIALS APPLICATIONS, [PMID:35689328] [10.1177/08853282221107951] |
| 3. Jia-Qi Huang, Lin-Ping Zhao, Xiang Zhou, Ling-Shan Liu, Rong-Rong Zheng, Fu-An Deng, Yi-Bin Liu, Xi-Yong Yu, Shi-Ying Li, Hong Cheng. (2022) Carrier Free O2-Economizer for Photodynamic Therapy Against Hypoxic Tumor by Inhibiting Cell Respiration. Small, 18 (15): (2107467). [PMID:35224854] [10.1002/smll.202107467] |
| 4. Can Wu, Chunlu Wang, Yaoyao Zheng, Yaxin Zheng, Ziqi Liu, Keming Xu, Wenying Zhong. (2021) Triple Enzyme-Regulated Molecular Hydrogels for Carrier-Free Delivery of Lonidamine. ADVANCED FUNCTIONAL MATERIALS, 31 (42): (2104418). [PMID:] [10.1002/adfm.202104418] |
| 5. Caixia Yue, Yuming Yang, Jie Song, Gabriel Alfranca, Chunlei Zhang, Qian Zhang, Ting Yin, Fei Pan, Jesús M. de la Fuente, Daxiang Cui. (2017) Mitochondria-targeting near-infrared light-triggered thermosensitive liposomes for localized photothermal and photodynamic ablation of tumors combined with chemotherapy. Nanoscale, 9 (31): (11103-11118). [PMID:28741634] [10.1039/C7NR02193C] |
| 6. Weiguo Song, Hekai Yang, Ying Wang, Shuzhen Chen, Wenda Zhong, Qian Wang, Wenshuo Ding, Guangzhao Xu, Chen Meng, Ying Liang, Zhe-Sheng Chen, Shuhua Cao, Liuya Wei, Fahui Li. (2024) Glutathione-Sensitive Photosensitizer–Drug Conjugates Target the Mitochondria to Overcome Multi-Drug Resistance in Cancer. Advanced Science, [PMID:38898730] [10.1002/advs.202307765] |
| 7. Haibin Lu, Weifang Tong, Meixu Jiang, Huimin Liu, Chen Meng, Kai Wang, Xupeng Mu. (2024) Mitochondria-Targeted Multifunctional Nanoprodrugs by Inhibiting Metabolic Reprogramming for Combating Cisplatin-Resistant Lung Cancer. ACS Nano, [PMID:39088743] [10.1021/acsnano.4c04024] |
| 8. Yimei Zhang, Shiyi Xiang, Yayi Wu, Can Yang, Dianyong Tang, Zhongzhu Chen, Zheng Huang. (2024) Novel co-delivery nanomedicine for photodynamic enlarged immunotherapy by cascade immune activation and efficient Immunosuppression reversion. BIOORGANIC CHEMISTRY, [PMID:39577155] [10.1016/j.bioorg.2024.107978] |
| 9. Jinchao Zhao, Lei Lei, Wenbin Dai, Angfeng Jiang, Qiao Jin, Zhe Tang. (2024) Simultaneous inhibition of heat shock proteins and autophagy enhances radiofrequency ablation of hepatocellular carcinoma. Biomaterials Science, [PMID:39429155] [10.1039/D4BM01190B] |
| 10. Junya Lu, Shuaipeng Feng, Zhu Liu, Yan Xiao, Hui Zhang, Siling Wang, Qinfu Zhao. (2025) Co-delivery of copper chelators and glycolytic inhibitors to disrupt glucose metabolism and inhibit tumor metastasis. CHEMICAL ENGINEERING JOURNAL, [PMID:] [10.1016/j.cej.2025.165899] |
| 11. Yimei Zhang, Chen Yuan, Wenwen Yang, Dianyong Tang, Zhongzhu Chen, Zheng Huang. (2025) Lonidamine dimer-based nanomedicine for overcoming multidrug resistance by manipulating energy metabolism and disrupting redox homeostasis. NEW JOURNAL OF CHEMISTRY, [PMID:] [10.1039/D5NJ02765A] |
| 12. Yingying Zhao, Beibei Zhang, Shaobo Duan, Yaqiong Li, Yuzhou Wang, Yongchao Wang, Juan Zhang, Rong Huang, Ru Jiang, Rui Zhang, Qi Zhou, Linlin Zhang, Xiaoxia Xu, Zesheng Li, Si Chen, Lianfeng Mo, Xu Zhang, Siyi Yang, Xiguo Cai, Lianzhong Zhang. (2025) An ultrasound-visualized methionine partitioning nano-modulator for enhanced immunotherapy against anti-PD-1 resistant tumors. CHEMICAL ENGINEERING JOURNAL, [PMID:] [10.1016/j.cej.2025.165409] |
| 13. Fangrong Tan, Yuandong Zeng, Donghua Dong, Yan Deng, Zhe Tang, LinGe Wang, Qianqian Yu. (2025) GSH-Responsive Prodrug Polymersomes for Copper-Free Cuproptosis and Synergistic Photothermal Cancer Therapy. BIOMACROMOLECULES, [PMID:41412815] [10.1021/acs.biomac.5c01893] |
| 14. Jing Zuo, Yichun Huang, Hailong Tian, Siyuan Qin, Yonghao Yan, Han Yan, Yining Jiang, Lei Li, Shiqi Wang, Yongfeng Jia, Yuan Zhao, Canhua Huang. (2026) H-ferritin engineered nanoplatform reprograms metabolism and immunity for glioblastoma immunotherapy. JOURNAL OF CONTROLLED RELEASE, [PMID:41506381] [10.1016/j.jconrel.2026.114613] |
| 15. Qianhua Feng, Yiwei Li, Liying Sun, Jia Zhang, Lisha Shou, Jieyu Zhu, Huimin Zhou, Bingqian Si, Xinyu Gu, Chunlei Du, Zhenzhong Zhang, Lei Wang. (2026) Probiotic Spore-Based Oral Biotherapeutics Promote Brain Targeting toward Gut-Brain Dual-Regulation for Parkinson’s Disease Treatment. ACS Nano, [PMID:41757540] [10.1021/acsnano.5c17340] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →